Altamira Collaborates To Evaluate CycloPhore™ Delivery For Partner’s Circular RNA Therapeutics

Altamira Therapeutics is a company focused on developing and marketing RNA delivery technology. The company has entered into a collaboration agreement with an undisclosed biotech company to explore the use of its CycloPhore™ RNA delivery platform for circular RNA (circRNA) therapeutics. CycloPhore is Altamira’s proprietary technology focused on delivering RNA payloads beyond the liver, which has traditionally been a challenge for RNA-based medicines.

“We are very excited to enter in this first collaboration to explore the utility of our CycloPhore platform”, commented Covadonga Pañeda, PhD, Altamira’s Chief Operating Officer. “CycloPhore was launched only recently specifically for delivery of circular RNA, which has been emerging as a highly promising approach for RNA drug development. For instance, circular mRNA could allow for lower dosing and less frequent administrations than linear mRNA. We look forward to working with our new partner who has strong expertise in circular RNA and the ambition to develop truly life changing therapeutics.”

The agreement outlines a plan for both in vitro and in vivo testing of the CycloPhore platform combined with the partner’s circRNA payloads. If initial evaluations are successful, the partner company has the option to enter into a license agreement with Altamira. This would allow for commercial development of circRNA nanoparticles using the CycloPhore platform.